Background: Melioidosis is a neglected tropical disease caused by the Gram-negative soil 24 bacterium Burkholderia pseudomallei. Current treatment regimens are prolonged and costly, 25 and acquired antimicrobial resistance has been reported for all currently used antibiotics. 26 Objectives: Efforts to develop new treatments for melioidosis are hampered by the risks 27 associated with handling pathogenic B. pseudomallei, which restricts research to facilities with 28 Biosafety Level (BSL) 3 containment. Closely related Burkholderia species that are less 29 pathogenic can be investigated under less stringent BSL 2 containment. We hypothesized that 30 near-neighbour Burkholderia species could be used as model organisms for developing 31 therapies that would also be effective against B. pseudomallei. 32 Methods: We used microbroth dilution assays to compare the susceptibility of three Australian 33 B. pseudomallei isolates and five near-neighbour Burkholderia species -B. humptydooensis, 34 B. thailandensis, B. oklahomensis, B territorii and B. stagnalis -to antibiotics currently used 35 to treat melioidosis, and general-use antibacterial agents. We also established the susceptibility 36 profiles of B. humptydooensis and B. territorii to 400 compounds from the Medicines for 37 Malaria Venture Pathogen Box. 38 Results: From these comparisons, we observed a high degree of similarity in the susceptibility 39 profiles of B. pseudomallei and near-neighbour species B. humptydooensis, B. thailandensis, 40 B. oklahomensis and B. territorii. 41 Conclusions: Less pathogenic Australian Burkholderia species B. humptydooensis, B. 42 thailandensis, B. oklahomensis and B. territorii are excellent model organisms for developing 43 potential new therapies for melioidosis.
Introduction 45
Burkholderia pseudomallei is a Gram-negative bacterium that causes melioidosis, 1, 2 a 46 neglected tropical disease with an estimated 165,000 cases and 89,000 deaths per year. 1 
47
Mortality rates for infected individuals vary between 10% in Darwin (Northern Territory, 48 Australia), 3 where state-of-the-art intensive care facilities are available; and over 40% in 49 endemic regions in southeast Asia, where health resources are more limited. 4 B. pseudomallei 50 is intrinsically resistant to many antibiotics, which limits treatment options; but importantly, 51 environmental isolates and primary B. pseudomallei isolates (from melioidosis patients prior 52 to antibiotic exposure) are almost universally susceptible to the first-line drugs used for 53 melioidosis therapy, including ceftazidime, meropenem and cotrimoxazole. 5-7 54 In instances where melioidosis is incorrectly diagnosed, initial treatment includes 55 conventional large spectrum antibiotic classes, such as aminoglycosides (e.g. streptomycin, 56 gentamicin and kanamycin), early generation β-lactam antibiotics (e.g. penicillin), 57 fluoroquinolones (e.g. ciprofloxacin) and macrolides (e.g. erythromycin). These generalised 58 treatments have little effect on B. pseudomallei, and therefore, result in a low rate of success 59 during periods of misdiagnosis. 6, [8] [9] [10] The limited effectiveness of many therapeutics against B. 60 pseudomallei is due to intrinsic and developed resistant to many antibiotics, via a number of 61 different mechanisms including reduced permeation, 11 drug efflux, 5, 12, 13 enzymatic drug 62 inactivation, 14, 15 or mutations. 16-18 63 The current therapeutic strategy for treating correctly diagnosed melioidosis patients 64 involves a two-phase schedule, comprising an acute intravenous phase followed by an oral 65 eradication phase. 19 The standard first-line therapy in Australia for the acute phase is 66 ceftazidime for 10 -14 days, while meropenem is used for severe infections or where treatment 67 with ceftazidime has failed. 6, 19 The length of the oral eradication phase, which is most 68 commonly co-trimoxazole (trimethoprim-sulfamethoxazole), is correlated with the success of treatment and reduction in frequency of relapse, often lasting four to six months. 6, 19, 20 The 70 prolonged nature of the melioidosis treatment schedule can lead to acquired resistance, a 71 significant event that has been linked to treatment failure and mortality in melioidosis patients 72 from the Northern Territory. 5 Prolonged and costly treatments are especially undesirable in 73 many regions where melioidosis is endemic, 1, 2, 8 and to overcome both intrinsic and acquired 74 antibiotic resistance, more efficacious therapeutics for the treatment of melioidosis are 75 required. 1 
Antibiotic panel 107
Antibiotics were selected to represent the current standard therapeutics for treating melioidosis, 108 ceftazidime, co-trimoxazole and meropenem; 6 and antibiotics more generally used in a clinical 109 setting for treating bacterial infections, such as doxycycline and amoxicillin. To allow a 110 broader characterisation, additional antibiotics with varying levels of efficacy against B. 111 pseudomallei 9, 40-46 were also included. A comprehensive overview of the therapeutic target, 112 mode of action, and expected dose required to inhibit 90% or 100% of B. pseudomallei growth 113 is shown for each of the antibiotics in Table S1 . 114 115
Antibiotic susceptibility profiles 116
Antimicrobial susceptibility testing was performed using a plate-based broth microdilution 117 method. 47 Briefly, assays were performed at 30 °C in Mueller Hinton broth (MHB) with 118 bacteria in mid log phase growth that were diluted to ~ 10 6 colony forming units/mL (OD600 = 119 0.001). Compounds were prepared in water or dimethyl sulfoxide (DMSO) and two-fold serial 120 dilutions in MHB were added to the bacteria (final bacterial concentration ~ 5 ´ 10 5 CFU/mL, 121 with a maximum of 0.64% (v/v) DMSO). The minimal inhibitory concentration (MIC) was 122 determined to be the lowest concentration of compound that inhibited visible bacterial growth 123 24 h after treatment. Resazurin (final concentration 0.001% (w/v)) was added to each well for 124 an additional one hour to confirm MIC visualisation. Resazurin (blue) is an oxidation-reduction 125 indicator of aerobic and anaerobic respiration and is converted to resorufin (pink) by viable 126 cells. MIC was determined from the well with the lowest compound concentration that 127 remained blue (no respiration). 128 129
Medicines for Malaria Venture (MMV) Pathogen Box compound susceptibility profiles 130
A Pathogen Box with 400 drug-like compounds was provided by the MMV. 48 Compounds 131 were supplied as 10 mM stock solutions in 100% DMSO, and were diluted in MHB according 132 to the suggested procedure in the Pathogen Box supporting documentation. Initial antimicrobial 133 susceptibility testing of the 400 compounds was performed at 20 µM, using the broth 134 microdilution method as described above. Ceftazidime (20 µM) was added as a control to each 135 plate as a positive control for 100% growth inhibition. 6 Subsequently, compounds with 136 observed activity at 20 µM were serially diluted to determine the MIC. Compound ID, 137 molecular weight, molecular formula and structure of compounds with activity against B. 138 humptydooensis and B. territorii at 20µM are provided in Figure S1 . derived from previous phylogenetic trees. 31, 33, 52 Lines represent relationships between the 157 species, but not genetic distance. Closed circles indicate Burkholderia species included in this 158 study. The species highlighted in bold are implicated in human disease. 159 160
Antibiotic susceptibility profiles for B. pseudomallei and near-neighbours 161
The aim of this investigation was to determine whether the susceptibility of B. pseudomallei to 162 a range of therapeutics used to treat melioidosis and generalised bacterial infections is 163 recapitulated by near-neighbour species. We hypothesized that species with similar antibiotic 164 susceptibility profiles to B. pseudomallei would have utility as less pathogenic models, to facilitate initial screening of new therapeutic molecules without the restrictive physical 166 containment requirements required for working with B. pseudomallei. 167
Current melioidosis treatment involves a regimen of antibiotics, including ceftazidime 168 or meropenem, with or without co-trimoxazole. Therefore, we compared the susceptibility of 169 B. pseudomallei near-neighbour species and B. pseudomallei isolates to these three key 170 antibiotics. B. pseudomallei isolates MSHR10517, MSHR2154 and MSHR1364 were inhibited 171 by 1 -3 mg/L of ceftazidime, 6 mg/L co-trimoxazole and 1 -2 mg/L of meropenem (Table 1) . 172
These values were consistent with previously reported MICs for other B. pseudomallei isolates 173 (see Table S1 ). 9, 41, 44, 53 By comparing the susceptibility of B. pseudomallei isolates 174 MSHR10517, MSHR2154 and MSHR1364 to the near-neighbour species, we found that the 175 B. pseudomallei susceptibility profile was best reflected by B. humptydooensis, which was 176 completely inhibited by 1 -3 mg/L ceftazidime, 6 -12 mg/L co-trimoxazole and 1 mg/L 177 meropenem. B. thailandensis and B. territorii also had similar MIC values for ceftazidime and 178 meropenem but were slightly more susceptible to co-trimoxazole (2 -3 mg/L). In contrast, B. 179 oklahomensis was two to four-fold more susceptible to ceftazidime and co-trimoxazole than 180 the B. pseudomallei isolates. B. stagnalis was two-fold less susceptible to ceftazidime (MIC 5 181 mg/L) and co-trimoxazole (MIC 6-12 mg/L), with greater than ten-fold reduced susceptibility 182 to meropenem (MIC of 14 -38 mg/L). Together, these susceptibility data show that B. 183 humptydooensis, B. thailandensis and B. territorii best represent the antibiotic susceptibility of 184 B. pseudomallei isolates for first-and second-line melioidosis therapies. 185
We also compared the activity of antibiotics that are commonly used to treat bacterial 186 infections (see Table 1 , general-use). Doxycycline showed potent activity toward B. 187 pseudomallei isolates (MIC 1 mg/L) that was consistent with previous reports. 9, 20 The near- pseudomallei, with less than two-fold difference in MIC values (see Table 1 ). Rifampicin had 196 poor activity against B. pseudomallei (MIC 8 -16 mg/L) that was consistent with previous 197 reports, 45 and in the current study it also showed poor potency against B. oklahomensis (MICs observed at these doses. Consistent with previous reports, amoxicillin, ampicillin, 205 clarithromycin gentamicin, puromycin, spectinomycin and streptomycin had no activity 206 against the B. pseudomallei isolates, 6, 9, 12, 44, 45 and these antibiotics also showed no activity 207 against the near-neighbour species at the tested concentrations. We additionally tested 208 antibiotics with limited or no previously reported susceptibilities to B. pseudomallei and 209
showed that cefsulodin and paromomycin were not active against any of the Burkholderia 210 species at the tested concentrations. 211
From these comparative antibiotic susceptibility screens, we showed that B. against key melioidosis therapeutics, as well as a number of other antibiotics used for treating 215 bacterial infections. Furthermore, the similarities in antibiotic susceptibility span across 216 multiple modes of action, including inhibition of cell wall synthesis, nucleic acid synthesis, 217 DNA replication, and protein synthesis. Therefore, we propose that these non-pathogenic 218
Burkholderia species can be used as model species to screen and identify novel antibiotics, and 219 to predict potency against B. pseudomallei. 220 Kanamycin 
Susceptibility of B. humptydooensis and B. territorii to MMV compounds 230
To further evaluate the suitability of the near-neighbour Burkholderia species as models for 231 predicting the drug susceptibility of B. pseudomallei, we examined the susceptibility of B. rifampicin, MMV675968, and MMV688271 (see Figure S1 for characteristics of the 240 compounds). An additional compound, MMV67968, showed novel activity toward the near-241 neighbour species. 242
Next, we determined the MICs toward B. humptydooensis and B. territorii for the 243 compounds identified from the initial screen, and for three additional compounds from a 244 previous B. pseudomallei susceptibility screen; 55 auranofin, miltefosine and MMV688179 (see 245 Table 2 and Table S1 ). The activities of doxycycline (MIC 0.5 -1 mg/L), levofloxacin ( MIC doxycycline and ceftazidime determined from the MMV compound screen ( Table 2 ) were in 250 close agreement with MICs from the antibiotic susceptibility screen ( Table 1 ). The MIC values 251 for auranofin, miltefosine and MMV688179 were at or above the highest concentration tested. 252
These high MICs are consistent with previous reports in B. pseudomallei 55 (see Table 2 ).
MMV675968 was active against B. humptydooensis and B. territorii, with MIC 254 between 3 -12 mg/L, an activity range that is within two-fold of the 'gold-standard' 255 melioidosis therapy ceftazidime. Therefore, this newly identified molecule is worthy of further 256 investigation for activity against B. pseudomallei. 257
Overall, comparison of the activity of the 400 tested MMV compounds against B. 258 humptydooensis and B. territorii provided independent correlation for four of the seven 259 compounds with previously identified activity against B. pseudomallei. 55 Although almost all 260
strains of B. pseudomallei tested have intrinsic resistance to gentamicin and streptomycin, 261 there have been rare reports of susceptibility to these antibiotics in isolates from Thailand and 262
Malaysia. 42, 56 These examples might suggest differences in susceptibility profiles of B. 263 pseudomallei isolates originating from different geographic regions; a question we have not 264 directly answered in this study. However, we show that these near-neighbour isolates provide 265 a strong prediction for susceptibility of Australian B. pseudomallei isolates, and can also 266 predict the susceptibility of clinical isolates of Mexican, Thai and Australian origin to 400 267 compounds. 55 ~ 0.115 a branch distances (in cm) were determined from a maximum-likelihood phylogeny (Figure 1 
